ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologicals"

  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: L13 • ACR Convergence 2024

    Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort

    Zahi Touma1, Ian Bruce2, Richard A. Furie3, Eric Morand4, Raj Tummala5, Shelly Chandran6, Gabriel Abreu7, Jacob Knagenhjelm7, Kellyn Arnold8, Hopin Lee8, Eleanor Ralphs8, Danuta Kielar9, Aleksander Bedenkov9 and Miina Waratani9, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2Queen's University Belfast, Belfast, United Kingdom, 3Northwell Health, Manhasset, NY, 4Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6Astrazeneca, Mississauga, ON, Canada, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8IQVIA, London, United Kingdom, 9Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
  • Abstract Number: L19 • ACR Convergence 2024

    Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

    Alexei Grom1, Uwe Ullman2, Adnan Mahmood3, Josefin Blomkvist3, Brian Jamieson4 and Fabrizio De Benedetti5, 1Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 2Sobi, Basel, Switzerland, 3Sobi, Stockholm, Sweden, 4Sobi, Inc., Morrisville, NC, 5Bambino Gesu Children's Hospital, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
  • Abstract Number: 0237 • ACR Convergence 2024

    Tofacitinib: A Retrospective Study on Safety and Adverse Effects

    Vrushal Kale1, Sandeep yadav2, Canchi Balakrishnan3, Rohini Samant4, Bishakha Swain4, Shaurav Khanna5, Aashish Agrawal5 and Aditi Patankar4, 1P D Hinduja national Hospital and medical Research centre, Mumbai, Maharashtra, India, 2Pd Hinduja hospital, Thane, Maharashtra, India, 3P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mahin, Maharashtra, India, 4P D Hinduja Hospital and Medical Research Centre, Mumbai, mumbai, Maharashtra, India, 5P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mumbai, Maharashtra, India

    Background/Purpose: Tofacitinib, an oral Janus kinase inhibitor, is widely used in India to treat rheumatoid arthritis (RA) and other autoimmune diseases. Although its efficacy is…
  • Abstract Number: 0468 • ACR Convergence 2024

    Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks

    David Stevens1, Lene Sundbakk2, Amirhossein Kazemi2, Marte Heiberg3, Tuulikki Sokka-Isler4, Bjorn Gudbjornsson5, Kristina Lend6, Anna Rudin7, Michael Nurmohamed8, Jon Lampa9, Merete Hetland10, Mikkel Ostergaard11, Ronald Van Vollenhoven12, Tillmann Uhlig2, Espen Haavardsholm2 and Hilde Hammer3, 1St. Olavs hospital, Trondheim, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Oslo, Norway, 4University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, 5Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 6Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 7Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 8Amsterdam University Medical Centers, Amsterdam, Netherlands, 9Karolinska University Hospital, Hässelby, Sweden, 10Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 11Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 12Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
  • Abstract Number: 0561 • ACR Convergence 2024

    Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort

    Annie Brink1, Elisabeth Mogard2, Elisabet Lindqvist2, Jonas Sagard2, Johan Karlsson Wallman1 and Tor Olofsson2, 1Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, 2Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden

    Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…
  • Abstract Number: 0745 • ACR Convergence 2024

    Tocilizumab in Monotherapy vs. Combined in Aortitis Associated with Giant Cell Arteritis. Multicenter Open-label Study of 196 Patients

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Javier Narvaez-García4, Olga Maíz Alonso5, Iñigo Hernández-Rodríguez6, Susana Romero Yuste7, Eugenio De Miguel8, Eva Galindez-Agirregoikoa9, ivan Ferraz-Amaro10, Julio Sánchez-Martín11, Patricia Moya Albarado12, Cristina Campos Fernández13, Fernando Lopez-Gutierrez14, Santos Castañeda15 and Ricardo Blanco-Alonso16, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario de Bellvitge, Barcelona, Spain, 53Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 6Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 7Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 8Hospital Universitario La Paz, Madrid, Spain, 9BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 10Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 11Hospital Universitario 12 de Octubre, Madrid, Spain, 12Hospital de San Pau, Barcelona, Spain, 13Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 14Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 15Hospital Universitario de la Princesa, Madrid, Spain, 16Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Aortitis related to Giant Cell Arteritis (GCA-aortitis) is a frequent and potential severe complication. Tocilizumab (TCZ) was approved in GCA, but the efficacy in…
  • Abstract Number: 1035 • ACR Convergence 2024

    Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

    Elisabet Castañeda Estévez1, Cristina Vergara Dangond1, Martina Steiner1, Maria Beatriz Paredes Romero1, Ana Esteban Vázquez1, Tatiana Cobo Ibañez1, Laura Trives Folguera1, Maria Liz Romero Bogado1, Isabel De La Cámara Fernandez1, Patricia Richi Alberti1, Ana Valeria Acosta Alfaro2, Iria De La Osa Subtil3 and Santiago Muñoz Fernández4, 1Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, 2Hospital Universitario Infanta Sofía., Madrid, Spain, 3Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid., Madrid, Spain, 4Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain

    Background/Purpose: Recently, the European Medicines Agency (EMA) published a health alert that extended to all JAK inhibitors (JAKi) due to a possible class effect, recommending…
  • Abstract Number: 1387 • ACR Convergence 2024

    Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

    Andrey Karateev1, Sofia Kuzkina2, Galym Togizbayev3, Elena Polishuk1, Ekaterina Filatova1, Vera Amirdzhanova1, Victoria Khlaboshchina1, Natalia Lapkina4, Andrey Baranov4 and Alexander Lila5, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Yaroslavl State Medical University, Yaroslavl, Russia, 5Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

    Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
  • Abstract Number: 1495 • ACR Convergence 2024

    Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

    Mawuena Binka1, Rana Muhammad Qasim Khan2, Joseph Tkacz3, Donna McMorrow3, Laurence Gozalo3 and Gail Kerr4, 1BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, 3Inovalon, Bowie, MD, 4Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
  • Abstract Number: 1864 • ACR Convergence 2024

    S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease

    Julia Manasson1, Marisella Panduro2, Michael Cianci2, Minasri Borah2, Stephanie Grebinoski2, Joshua Vitlip2, Stephen Lutz2, Ishan Sharma2, Elliott Wittenberg2, Allison Colthart2, Samuel Perry2, Maria Cecilia Ramello2, Chelsea R. Parker Harp2, Jyothsna Visweswaraiah2, Ryan Peckner2, Alex Pellerin2, Heather Vital3, John Sundy4, Nathan Higginson-Scott2, Kevin L. Otipoby2 and Daniela Cipolletta2, 1Seismic Therapeutic, New York, NY, 2Seismic Therapeutic, Watertown, MA, 3Seismic Therapeutic, Lexington, MA, 4Seismic Therapeutic, Chapel Hill, NC

    Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…
  • Abstract Number: 2144 • ACR Convergence 2024

    Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab

    Jean-Yves Reginster1, Stuart L. Silverman2, Edward Czerwinski3, Przemyslaw Borowy4, Tomasz Budlewski5, Joanna Kwiatek6, Svitlana Postol7, Airi Põder8, Jerzy Supronik9, SungHyun Kim10, JeeHye Suh10, GoEun Yang10, NooRi Han10, NaHyun Kim10 and SeoHee Bae10, 1Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, 2OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, 3Krakowskie Centrum Medyczne, Kraków, Poland, 4Krakowskie Centrum Medyczne, Krakow, Poland, 5Department of Rheumatology, Medical University of Lodz, Lodz, Poland, 6Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, 7Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, 8Clinical Research Centre Ltd, Tartu, Estonia, 9Osteo-Medic s.c., Białystok, Poland, 10Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…
  • Abstract Number: 2364 • ACR Convergence 2024

    Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis

    Marina Magrey1, Denis Poddubnyy2, Mark Lebwohl3, Rajan Bajracharya4, Dirk de Cuyper5, Alexander Marten6, Luke Peterson7, Jeffrey L. Stark8 and Joseph F. Merola9, 1Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 2Charite-Universitatsmedizin Berlin, Berlin, Germany, 3Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Morrisville, NC, 8UCB Pharma, Smyrna, GA, 9UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Anxiety and depression are highly prevalent in patients (pts) with axial spondyloarthritis (axSpA)/PsA.1,2 We report mental health data in pts with axSpA/PsA from trials…
  • Abstract Number: 2609 • ACR Convergence 2024

    Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry

    Eric Roberts1, Nick Bansback2, Chien-Wen Tseng3, Steve Shiboski4, Jing Li5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1University of California, San Francisco, SF, CA, 2University of British Columbia, Vancouver, BC, Canada, 3University of Hawai'i John A. Burns School of Medicine, Honolulu, 4University of California, San Francisco, San Francisco, 5University of California, San Francisco, San Francisco, CA, 6UCSF / SFVA, San Francisco, CA, 7UCSF, San Francisco, CA

    Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
  • Abstract Number: 0243 • ACR Convergence 2024

    Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment

    Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia

    Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
  • 1
  • 2
  • 3
  • …
  • 54
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology